Last updated: April 24, 2026
AZURITY PHARMACEUTICALS, INC. v. AMNEAL PHARMACEUTICALS LLC (D.N.J.) | Case 1:21-cv-08717: Litigation Summary and Patent-Strategy Analysis
What is the case and where is it filed?
- Parties: Azurity Pharmaceuticals, Inc. (plaintiff) vs. Amneal Pharmaceuticals LLC (defendant)
- Docket: 1:21-cv-08717
- Court: U.S. District Court for the District of New Jersey
- Case type (procedural posture): Patent infringement litigation arising from an ANDA pathway under the Hatch-Waxman Act (carriage and typical posture in this docket class; specific asserted-document set is not provided in the input record).
What claims and patents are at issue?
The input does not include the complaint caption details, asserted patent numbers, counts, claim chart excerpts, or scheduling/order docket items, so a complete, accurate litigation map cannot be produced from the provided information. Under the constraints, no partial reconstruction is provided.
How did the dispute typically frame liability in this procedural posture?
In ANDA-related patent suits, the infringement theory and defenses ordinarily center on:
- Patent infringement allegations tied to specific claims of one or more Orange Book-listed patents.
- ANDA paragraph certifications (often Paragraph IV, in some cases Paragraph III) linked to expiry status and noninfringement/invalidity positions.
- Core defenses:
- Noninfringement (no claim coverage under the proposed ANDA product)
- Invalidity (anticipation, obviousness, lack of enablement/indefiniteness, prosecution history, or other statutory grounds)
- Evidentiary disputes over claim construction and product equivalence
This framework is standard for the procedural class reflected by AZURITY v. AMNEAL filings, but the precise arguments and outcome cannot be stated without the complaint, claim-construction orders, summary judgment rulings, or trial record.
What is the litigation timeline and status?
The input record contains only the case identification string (AZURITY PHARMACEUTICALS, INC. v. AMNEAL PHARMACEUTICALS LLC | 1:21-cv-08717). No filing dates, claim-construction dates, motion deadlines, settlement dates, or disposition orders are included. A timeline cannot be produced without those docket entries.
What does the case likely signal for patent strategy in this space?
Without the asserted patents, product, and litigated positions, only high-level strategy themes can be described, which would not meet the standard for a hard-data litigation analysis.
Bottom-line business implications
A credible business assessment requires at minimum:
- asserted patent list and asserted claims
- Markman outcome
- infringement/invalidity rulings
- any settlement agreement terms tied to launch and exclusivity (if present)
None of these are available in the provided input, so no definitive investment or R&D action signal is issued.
Key Takeaways
- Case identification is confirmed: AZURITY PHARMACEUTICALS, INC. v. AMNEAL PHARMACEUTICALS LLC, 1:21-cv-08717, U.S. District Court for the District of New Jersey.
- A complete litigation summary cannot be produced from the provided record because it lacks asserted patents, complaint allegations, docket dates, claim construction, dispositive motions, and final disposition.
- No outcome or patent-strength conclusion is stated under the accuracy constraint.
FAQs
-
What court heard AZURITY v. AMNEAL?
U.S. District Court for the District of New Jersey, docket 1:21-cv-08717.
-
Is this an ANDA Hatch-Waxman patent case?
The case identification matches the procedural class typically associated with ANDA-related patent infringement suits, but the specific ANDA and certification paragraph are not included in the provided record.
-
Which patents did Azurity assert?
Not provided in the input record; cannot be stated accurately.
-
Did the court issue a Markman (claim construction) ruling?
Claim construction orders are not included in the input record; cannot be stated accurately.
-
What was the outcome (win/lose, settlement, injunction)?
No disposition data is included in the input record; cannot be stated accurately.
References
[1] Case docket: AZURITY PHARMACEUTICALS, INC. v. AMNEAL PHARMACEUTICALS LLC, 1:21-cv-08717, U.S. District Court for the District of New Jersey.
